Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions
DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).
- Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally.
- With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.
- Dr. Gunn commented, “We are fully prepared to make Velocity the first-choice site network for liver disease clinical trials worldwide.
- Velocity has over 80 locations globally and access to more than 220 principal investigators and one million patients.